|
Anaplastic astrocytoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
33-year-old nulligravid woman with newly diagnosed anaplastic astrocytoma (AA; WHO grade III, IDH1-negative) sought fertility preservation.
|
29739361 |
2018 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Astrocytoma (grade III) are frequently mutated in isocitrate dehydrogenase (IDH1).
|
31039537 |
2019 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations were frequent in low-grade diffuse astrocytomas (88%) and in secondary glioblastomas that developed through progression from low-grade diffuse or anaplastic astrocytoma (82%).
|
19246647 |
2009 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 mutations are frequent (>80%) in secondary glioblastomas that have progressed from low-grade or anaplastic astrocytomas.
|
21442241 |
2011 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
|
24748470 |
2014 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
|
25962792 |
2015 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A second surgery was performed, and pathology demonstrated recurrent tumor, consistent with IDH1-mutated anaplastic astrocytoma.
|
26911558 |
2016 |
|
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among IDH1-mutated astrocytomas no significant difference in survival was shown between DA and AA.
|
28214203 |
2017 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An important underlying observation was that patients with anaplastic astrocytomas (AA) without IDH mutation had a clinical course similar to that of patients with glioblastomas (GBM).
|
31623667 |
2019 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene.
|
24149775 |
2014 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both Grade II gliomas and anaplastic astrocytomas showed a statistically different distribution of IDH1 mutation load compared to GBMs (p < 0.0001; p = 0.0021 respectively).
|
23451940 |
2013 |
|
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
|
24777756 |
2014 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Diffuse astrocytoma (DA), anaplastic astrocytoma (AA), and glioblastoma (GBM) are defined by the World Health Organization (WHO) based on IDH-mutational status.
|
28110298 |
2017 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
|
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report the generation of an endogenous IDH1 anaplastic astrocytoma model which rapidly grows in vivo, produces 2-HG and exhibits DNA hypermethylation.
|
24077805 |
2013 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IHC detected the IDH1 mutation in 72% (13/18) anaplastic astrocytomas and 30% (3/10) astrocytomas; however, it failed to detect the mutation in 258 thyroid, 11 renal cell, 10 ovarian, 18 endometrial, 20 breast, 25 colorectal, 22 non-small cell lung carcinoma, 25 melanomas, and 8 thyroid follicular adenomas.
|
23235339 |
2014 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the anti-IDH1-R132H-specific monoclonal antibody IMab-1 is very useful for detecting IDH1-R132H in immunohistochemistry, and predicting the time to progression in grade III anaplastic astrocytomas.
|
21344322 |
2011 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, high expression of PROX1 protein predicted shorter survival in the group of patients with IDH-mutant anaplastic astrocytomas and secondary glioblastomas.
|
27626492 |
2016 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors.
|
30072066 |
2018 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis demonstrated that T2-EOR (HR 3.28; 95% CI 1.22-8.81; p = 0.0192) and IDH1 mutation (HR 3.90; 95% CI 1.53-10.75; p = 0.0044) were predictive of survival in patients with AA and AOA.
|
28885120 |
2018 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with anaplastic astrocytomas.
|
19765000 |
2009 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study confirms the utility of IDH1 mutations and MGMT methylation in predicting the prognosis of Group 1 patients (GBM + AA) and demonstrated that IDH1 mutations may serve as a more reliable prognostic factor for such patients.
|
24160898 |
2013 |
|
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |